Welcome to our dedicated page for Cue Biopharma SEC filings (Ticker: CUE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
R&D expenses that double every quarter, complex collaboration revenue notes, and pages of clinical trial risk factors—Cue Biopharma’s SEC filings can feel like a scientific paper wrapped in legal jargon. Yet those disclosures hide the signals investors crave: when Immuno-STAT trials hit a milestone, how much cash runway remains, and whether insiders are quietly buying shares.
StockTitan’s AI decodes each document in minutes. Need the Cue Biopharma quarterly earnings report 10-Q filing? You’ll get real-time alerts plus an AI-powered summary that translates biotech accounting into plain English. Wondering about Cue Biopharma insider trading Form 4 transactions? We flag executive stock moves the moment they post to EDGAR and map them against upcoming data readouts. From the exhaustive annual report—your Cue Biopharma annual report 10-K simplified—to every 8-K material event explained, our platform covers every filing type with expert context and historical comparisons.
Here’s how professionals use the page:
- Track Cue Biopharma Form 4 insider transactions real-time to gauge management confidence before Phase 1/2 updates.
- Compare R&D spend across quarters without wading through footnotes—Cue Biopharma earnings report filing analysis makes it clear.
- Quickly locate equity-compensation tables inside the Cue Biopharma proxy statement executive compensation.
Whether you’re parsing an 8-K for FDA feedback or understanding Cue Biopharma SEC documents with AI, StockTitan turns dense biotech disclosures into actionable insight—no PhD required.
Cue Biopharma, Inc. reported that on November 24, 2025 it made an updated corporate presentation publicly available on its website and furnished that presentation as Exhibit 99.1 to a Form 8-K. The company notes that the materials provided under Item 7.01, including the presentation, are being furnished rather than filed under the Exchange Act, which means they are not subject to certain liabilities associated with filed reports and are not automatically incorporated into other securities filings unless specifically referenced.
Cue Biopharma, Inc. (CUE) announced that Chief Medical Officer Matteo Levisetti will leave the company, with his employment ending on November 28, 2025. The company and Dr. Levisetti agreed to his separation on November 17, 2025.
Subject to signing and not revoking a separation and release of claims agreement, Dr. Levisetti will receive a lump-sum cash severance of $556,837.60, equal to nine months of base salary plus a prorated portion of his 2025 target bonus, paid in the first regular payroll cycle after the separation agreement becomes effective. If he elects COBRA coverage, Cue Biopharma will pay the full premiums for up to nine months after the Separation Date, or until he secures reasonably comparable new coverage or COBRA otherwise ends.
Cue Biopharma reported third‑quarter results, highlighting lower collaboration revenue and continued operating losses, alongside a new collaboration that adds near‑term cash. Collaboration revenue was
Liquidity remained tight with cash, cash equivalents and marketable securities of
Cue Biopharma (CUE) reported that it issued a press release with financial results for the quarter ended September 30, 2025. The release is furnished as Exhibit 99.1.
The company notes that the information in this report, including Exhibit 99.1, is being furnished and is not deemed “filed” under Section 18 of the Exchange Act or incorporated by reference, except as expressly set forth by specific reference.
Cue Biopharma (CUE) announced a Collaboration and License Agreement with ImmunoScape Pte. Ltd. (IMSCP), following IMSCP’s exercise of an option on
The structure grants IMSCP a co-exclusive development license for five years or longer (while a specified number of CUE‑100 Series molecules remain under active development), with Cue retaining non‑exclusive research rights to support other programs. IMSCP also receives an exclusive commercial license for any CUE‑100 Series molecule it advances to IND‑enabling studies during the co‑exclusive period.
Cue received
Cue Biopharma director and CEO Usman Azam was granted a stock option on 09/29/2025 to purchase 1,875,000 shares of common stock at an exercise price of $0.72 per share. The option was reported on Form 4 filed 10/02/2025 and becomes exercisable in 48 monthly installments beginning 09/29/2026, with an expiration date of 09/28/2035. After the grant, Azam beneficially owns 1,875,000 underlying shares directly. The filing was signed by an attorney-in-fact on Azam's behalf.
Usman Azam filed a Form 3 reporting his relationship to Cue Biopharma, Inc. (CUE) as both a director and the Chief Executive Officer. The form shows the date of event as 09/29/2025 and states that no securities are beneficially owned by the reporting person as of the filing. The filing was executed by an attorney-in-fact on 10/02/2025 and includes an exhibit: Exhibit 24.1 - Power of Attorney.
Cue Biopharma filed a Form S-8 to register securities under its 2025 Stock Incentive Plan, enabling the company to grant equity awards to employees, directors and other service providers. The registration statement incorporates by reference the company’s annual report for the fiscal year ended December 31, 2024, its quarterly reports for the quarters ended March 31, 2025 and June 30, 2025, and a set of current reports and other SEC filings, and it updates the company’s description of its common stock via Exhibit 4.2 to the 2024 annual report.
The filing omits plan narrative from Part I because those documents were provided separately to plan participants under Rule 428; exhibits included or incorporated by reference cover the 2025 Stock Incentive Plan, the amended and restated certificate of incorporation and bylaws, legal opinion and auditor consents, a power of attorney and the calculation of filing fee tables. The statement also summarizes the company’s indemnification framework for directors and officers, including indemnification agreements and directors’ and officers’ liability insurance.
Cue Biopharma reported continued clinical-stage operating losses while taking steps to bolster liquidity through financing and partnerships. The company held $27.5 million of cash and cash equivalents as of June 30, 2025 and reported a net loss of $20.7 million for the six months ended June 30, 2025 (net loss of $8.48 million for the quarter). Accumulated deficit was $362.6 million and weighted average shares outstanding increased to 84.86 million for the six-month period.
The company raised capital through a 2025 public offering that generated $18.0 million net proceeds, modest ATM proceeds during the period, and received a $10.1 million upfront payment from a collaboration and license agreement with Boehringer Ingelheim (BI) that also includes up to approximately $345 million in potential milestones and royalties. Management discloses substantial doubt about the company’s ability to continue as a going concern and notes all Term Loans are due December 1, 2025.
FAQ
What is the current stock price of Cue Biopharma (CUE)?
What is the market cap of Cue Biopharma (CUE)?
